Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine

The benzoate salt of 5MeODMT addresses the mucosal irritation issue of hydrochloride salts by offering reduced irritation and improved nasal permeation, suitable for inhalation delivery.

AU2021289147B2Pending Publication Date: 2026-07-23BECKLEY PSYTECH LIMITED
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
BECKLEY PSYTECH LIMITED
Filing Date
2021-06-14
Publication Date
2026-07-23

AI Technical Summary

Technical Problem

Existing formulations of 5-methoxy-N,N-dimethyltryptamine (5MeODMT) are highly irritating to the mucosal lining, and the hydrochloride salt, while effective for crystallization, remains irritating, necessitating a less irritating alternative for mucosal delivery.

Method used

The synthesis of the benzoate salt of 5MeODMT, which is less irritating and exhibits higher permeation across the nasal epithelium, is developed through a series of chemical reactions and spray drying processes.

Benefits of technology

The benzoate salt of 5MeODMT provides reduced mucosal irritation and enhanced permeation, making it an ideal candidate for inhalation delivery with potentially lower dosages required for efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000089_0000
    Figure 00000089_0000
  • Figure 00000090_0000
    Figure 00000090_0000
  • Figure 00000091_0000
    Figure 00000091_0000
Patent Text Reader

Abstract

A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).
Need to check novelty before this filing date? Find Prior Art